.png)
.png)
SVP, Clinical Development
Spero Therapeutics
Disclosure(s): Spero Therapeutics: Employee, Stocks/Bonds
Angela Talley, MD is Senior Vice President of Clinical Development at Spero Therapeutics. Dr. Talley has worked in anti-infective clinical research and drug development in both academia and industry for over 15 years, leading anti-infective programs in Phase I-IV development. During her time in industry, she been involved in the development of several approved and/or candidate antibiotics including ceftazidime-avibactam, ceftaroline, aztreonam-avibactam, dalbavancin, and Spero’s programs for tebipenem HBr, SPR720 and SPR206. Dr. Talley received her M.D. from Mount Sinai School of Medicine and completed internship and residency in Internal Medicine at Columbia-Presbyterian Medical Center and Infectious Disease Fellowship at the University of Washington.